Literature DB >> 25398241

Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.

Jason M Wiebelhaus1, Travis W Grim2, Robert A Owens2, Matthew F Lazenka2, Laura J Sim-Selley2, Rehab A Abdullah2, Micah J Niphakis2, Robert E Vann2, Benjamin F Cravatt2, Jenny L Wiley2, S Stevens Negus2, Aron H Lichtman2.   

Abstract

A growing body of evidence implicates endogenous cannabinoids as modulators of the mesolimbic dopamine system and motivated behavior. Paradoxically, the reinforcing effects of Δ(9)-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis, have been difficult to detect in preclinical rodent models. In this study, we investigated the impact of THC and inhibitors of the endocannabinoid hydrolytic enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) on operant responding for electrical stimulation of the medial forebrain bundle [intracranial self-stimulation (ICSS)], which is known to activate the mesolimbic dopamine system. These drugs were also tested in assays of operant responding for food reinforcement and spontaneous locomotor activity. THC and the MAGL inhibitor JZL184 (4-[bis(1,3-benzodioxol-5-yl)hydroxymethyl]-1-piperidinecarboxylic acid 4-nitrophenyl ester) attenuated operant responding for ICSS and food, and also reduced spontaneous locomotor activity. In contrast, the FAAH inhibitor PF-3845 (N-3-pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxamide) was largely without effect in these assays. Consistent with previous studies showing that combined inhibition of FAAH and MAGL produces a substantially greater cannabimimetic profile than single enzyme inhibition, the dual FAAH-MAGL inhibitor SA-57 (4-[2-(4-chlorophenyl)ethyl]-1-piperidinecarboxylic acid 2-(methylamino)-2-oxoethyl ester) produced a similar magnitude of ICSS depression as that produced by THC. ICSS attenuation by JZL184 was associated with increased brain levels of 2-arachidonoylglycerol (2-AG), whereas peak effects of SA-57 were associated with increased levels of both N-arachidonoylethanolamine (anandamide) and 2-AG. The cannabinoid receptor type 1 receptor antagonist rimonabant, but not the cannabinoid receptor type 2 receptor antagonist SR144528, blocked the attenuating effects of THC, JZL184, and SA-57 on ICSS. Thus, THC, MAGL inhibition, and dual FAAH-MAGL inhibition not only reduce ICSS, but also decrease other reinforced and nonreinforced behaviors.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25398241      PMCID: PMC4293433          DOI: 10.1124/jpet.114.218677

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  55 in total

1.  Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum.

Authors:  Erik B Oleson; Michael V Beckert; Joshua T Morra; Carien S Lansink; Roger Cachope; Rehab A Abdullah; Amy L Loriaux; Dustin Schetters; Tommy Pattij; Mitchell F Roitman; Aron H Lichtman; Joseph F Cheer
Journal:  Neuron       Date:  2012-01-26       Impact factor: 17.173

Review 2.  A brain on cannabinoids: the role of dopamine release in reward seeking.

Authors:  Erik B Oleson; Joseph F Cheer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

3.  Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure.

Authors:  Carl L Hart; Margaret Haney; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2005-04-14       Impact factor: 4.530

4.  Dissociable effects of the cannabinoid receptor agonists Δ9-tetrahydrocannabinol and CP55940 on pain-stimulated versus pain-depressed behavior in rats.

Authors:  Andrew J Kwilasz; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2012-08-14       Impact factor: 4.030

Review 5.  Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders.

Authors:  Javier Fernández-Ruiz; Mariluz Hernández; José A Ramos
Journal:  CNS Neurosci Ther       Date:  2010-04-12       Impact factor: 5.243

6.  Neurophysiological and cognitive effects of smoked marijuana in frequent users.

Authors:  Carl L Hart; Aaron B Ilan; Alan Gevins; Erik W Gunderson; Kemi Role; Jana Colley; Richard W Foltin
Journal:  Pharmacol Biochem Behav       Date:  2010-06-18       Impact factor: 3.533

7.  Alcohol, cocaine, and brain stimulation-reward in C57Bl6/J and DBA2/J mice.

Authors:  Eric W Fish; Thorfinn T Riday; Megan M McGuigan; Sara Faccidomo; Clyde W Hodge; C J Malanga
Journal:  Alcohol Clin Exp Res       Date:  2009-10-23       Impact factor: 3.455

8.  O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors.

Authors:  Micah J Niphakis; Douglas S Johnson; T Eric Ballard; Cory Stiff; Benjamin F Cravatt
Journal:  ACS Chem Neurosci       Date:  2011-10-10       Impact factor: 4.418

9.  Dual fatty acid amide hydrolase and monoacylglycerol lipase blockade produces THC-like Morris water maze deficits in mice.

Authors:  Laura E Wise; Kelly A Long; Rehab A Abdullah; Jonathan Z Long; Benjamin F Cravatt; Aron H Lichtman
Journal:  ACS Chem Neurosci       Date:  2012-01-27       Impact factor: 4.418

10.  Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats.

Authors:  S Stevens Negus; Ember M Morrissey; Marisa Rosenberg; K Cheng; Kenner C Rice
Journal:  Psychopharmacology (Berl)       Date:  2010-01-26       Impact factor: 4.530

View more
  22 in total

1.  Neuroprotective effects of fatty acid amide hydrolase catabolic enzyme inhibition in a HIV-1 Tat model of neuroAIDS.

Authors:  Douglas J Hermes; Changqing Xu; Justin L Poklis; Micah J Niphakis; Benjamin F Cravatt; Ken Mackie; Aron H Lichtman; Bogna M Ignatowska-Jankowska; Sylvia Fitting
Journal:  Neuropharmacology       Date:  2018-08-13       Impact factor: 5.250

2.  Cannabinoid CB1 and CB2 receptor mechanisms underlie cannabis reward and aversion in rats.

Authors:  Krista J Spiller; Guo-Hua Bi; Yi He; Ewa Galaj; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Br J Pharmacol       Date:  2019-04-03       Impact factor: 8.739

3.  Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice.

Authors:  Robert A Owens; Bogna Ignatowska-Jankowska; Mohammed Mustafa; Patrick M Beardsley; Jenny L Wiley; Abdulmajeed Jali; Dana E Selley; Micah J Niphakis; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2016-06-15       Impact factor: 4.030

4.  Attenuated dopamine receptor signaling in nucleus accumbens core in a rat model of chemically-induced neuropathy.

Authors:  Dana E Selley; Matthew F Lazenka; Laura J Sim-Selley; Julie R Secor McVoy; David N Potter; Elena H Chartoff; William A Carlezon; S Stevens Negus
Journal:  Neuropharmacology       Date:  2020-01-07       Impact factor: 5.250

5.  Role of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Δ9-Tetrahydrocannabinol-Mediated Induction of ΔFosB in the Mouse Forebrain.

Authors:  Matthew F Lazenka; Aaron J Tomarchio; Aron H Lichtman; Paul Greengard; Marc Flajolet; Dana E Selley; Laura J Sim-Selley
Journal:  J Pharmacol Exp Ther       Date:  2015-06-22       Impact factor: 4.030

6.  Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Δ9-tetrahydrocannabinol in mice.

Authors:  Lenka Hruba; Alexandre Seillier; Armia Zaki; Benjamin F Cravatt; Aron H Lichtman; Andrea Giuffrida; Lance R McMahon
Journal:  J Pharmacol Exp Ther       Date:  2015-02-24       Impact factor: 4.030

Review 7.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

8.  Effects of Acute and Repeated Administration of Oxycodone and Naloxone-Precipitated Withdrawal on Intracranial Self-Stimulation in Rats.

Authors:  Jason M Wiebelhaus; D Matthew Walentiny; Patrick M Beardsley
Journal:  J Pharmacol Exp Ther       Date:  2015-10-21       Impact factor: 4.030

Review 9.  Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg.

Authors:  Gianluigi Tanda
Journal:  Psychopharmacology (Berl)       Date:  2016-03-30       Impact factor: 4.530

10.  Acute Ethanol Inhibition of Adult Hippocampal Neurogenesis Involves CB1 Cannabinoid Receptor Signaling.

Authors:  Dal Khatri; Genevieve Laroche; Marion L Grant; Victoria M Jones; Ryan P Vetreno; Fulton T Crews; Somnath Mukhopadhyay
Journal:  Alcohol Clin Exp Res       Date:  2018-03-07       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.